The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
12 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,613,509 in first-year total cost, median $251,335.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMNR-W (10)]4
- Special Emphasis Panel[ZRG1 DKUS-L (11)]2
- Special Emphasis Panel[ZRG1 MOSS-C (12)]2
- Special Emphasis Panel[ZRG1 BST-R (10)]1
- Special Emphasis Panel[ZRG1 DKUS-R (10)]1
Most frequent institutions
- ELIXERA, INC.2
- AVM BIOTECHNOLOGY, LLC1
- BIOORG3.14, LLC1
- ION CHANNEL PHARMACOLOGY1
- LAMASSU PHARMA INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Development of a novel lipase inhibitor for the treatment of acute pancreatitis1R44DK125219-01 | HANNA, GABI | LAMASSU PHARMA INC., NC | $1,498,822 | ZRG1 |
| 2020 | DEVELOPMENT AND TESTING OF SUBCUTANEOUS CSD PEPTIDE FORMULATIONS FOR CHRONIC KIDNEY DISEASE1R43DK124010-01A1 | MACKENZIE, BREANNE | LUNG THERAPEUTICS, INC., TX | $300,228 | ZRG1 |
| 2020 | A First-in-Class Antibody Therapeutic for Treatment of Acromegaly1R43DK126579-01 | ZANGHI, JAMES | ELIXERA, INC., CA | $284,100 | ZRG1 |
| 2019 | MAP: a Flowable, Precision-Engineered, and Tunable Tissue Scaffold Leveraging Hyper-Porous Geometry to Control Inflammation and Promote Regenerative Healing in Diabetic Wounds1R44DK124085-01 | DESHAYES, STEPHANIE | TEMPO THERAPEUTICS, INC., CA | $737,053 | ZRG1 |
| 2019 | The effects of protein kinase C epsilon peptide inhibitor (YT-001) in warm murine kidney ischemia-reperfusion1R43DK121626-01A1 | YOUNG, LINDON H | YOUNG THERAPEUTICS, LLC, PA | $300,000 | ZRG1 |
| 2019 | A First-in-Class Human Antibody Therapeutic for Treatment of Cushing's Disease1R43DK123901-01 | ZANGHI, JAMES | ELIXERA, INC., CA | $224,624 | ZRG1 |
| 2019 | Development and evaluation of a polymer coated proprietary cream formulation of resiniferatoxin nanoparticles for the treatment of pain associated with Diabetic Peripheral Neuropathy1R43DK117674-01A1 | PREMKUMAR, LOUIS S | ION CHANNEL PHARMACOLOGY, IL | $215,841 | ZRG1 |
| 2019 | Targeted lympho-ablation as an alternative to HSCT to cure T1D1R43DK121634-01A1 | DEISHER, THERESA | AVM BIOTECHNOLOGY, LLC, WA | $211,047 | ZRG1 |
| 2019 | Determining Effectiveness of V-10 Self-Assembling Pro-Angiogenic Peptide in Re-Vascularizing and Accelerating Wound-Healing in a BBZDR Rat Model of Diabetic Foot Ulceration1R43DK121599-01 | CHOUDHURY, MARWA | NANGIOTX, INC., NJ | $115,900 | ZRG1 |
| 2018 | Designed Host Defense Pepties for the Topical Treatment of Diabetic Foot Ulcers1R43DK116503-01A1 | CLEMENS, LOUIS EDWARD | RIPTIDE BIOSCIENCE, INC., CA | $278,046 | ZRG1 |
| 2018 | Development of stapled oxyntomodulin-Fc fusion proteins for the treatment of diabetes and obesity1R43DK117740-01 | LIN, QINGYANG, YIFANG | TRANSIRA THERAPEUTICS, LLC, NY | $224,000 | ZRG1 |
| 2018 | A diabetes pill to replace insulin injections1R44DK120248-01 | WASHINGTON, ILYAS | BIOORG3.14, LLC, WY | $223,848 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.